So much this!! Absolutely spot on.

First 23 Last

Share
Profile

Follow
polarbear666

4,181 Posts.

2291

18/10/19

15:47

Post #: 40956557
Share

Originally posted by AimForSimon: ↑

So Afterpay prevent a retailer from charging a fee? Last time I looked at retailers they can charge what every they want. if retailer feels inclined to add 4% to the price of their product then the demand curve will move down.

Maybe the RBA should regulate sales and discounts as well.

The commentary coming out of the media analysts and now supposedly the RBA is rubbish.

let's look at facts :

1. AFR has always hated APT so nothing new here other than UBS gave them something to write about.

2. The UBS report was written by a Bank and Credit analyst duo not a consumer fin tech growth business analyst. All they identified were pitfalls. That is why they are bank analysts and not billionaire internet entrepreneurs.

3. APT is a significant driver of traffic to retailers. As I said above if they want to charge for Afterpay fees let them do it. they will lose sales which was the reason why they signed up for Afterpay in the first place. Not for a regulator to tell them how to charge for their product.

This was terrible research that only looks at what could go wrong and then value it based on all the negatives.

I don't know where the bottom is but it is feeling like the last round of AFR beat ups and ill informed regulator probes.

Funny to watch and listen to everyone though.

Maximum fear coming but all I know is I think I want to be long before the next update comes and shows that Australia is becoming a smaller part of the pie.

DYOR

Expand

So much this!! Absolutely spot on.

APT Price at posting: $29.75 Sentiment: Buy Disclosure: Held
9 Upvote

0 Great analysis

Reply

Top Stories

LU7

Strong PFS numbers solidify Lithium Universe's big plans for Québec

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Failure to report prompts ASX to impose multiple company suspensions

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

IRE

Iress runs 'hot' for Wealth Within's stock tips